Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial - Isa, Flonza; Gonzalez Ortiz, Ana M; Meyer, Jonathan; Hamilton, Jennifer D; Olenchock, Benjamin A; Brackin, Taylor; Ganguly, Samit; Forleo-Neto, Eduardo; Faria, Lori; Heirman, Ingeborg; Marovich, Mary; Hutter, Julia; et al. (The Lancet infectious diseases, 2025)
Keywords: 2019-nCoV Vaccine mRNA-1273; Adult; Adverse events; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - immunology; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Blood; COVID-19; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - adverse effects; COVID-19 Vaccines - immunology; Dilution; Disease prevention; Epitopes; Female; Health services; Humans; Immune response; Immune system; Immunity (Disease); Infectious diseases; Intravenous administration; Labels; Lymphocytes B; Lymphocytes T; Male; Middle Aged; Monoclonal antibodies; mRNA; Prospective Studies; Proteins; Public health; Randomization; Safety analysis; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - immunology; Spike protein; Vaccination - methods; Vaccines; Viral diseases; United States--US